Publications
5600 Results
- Journal / Conference
- ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), poster
- Year
- 2024
- Research Committee(s)
- Leukemia
4q Copy Neutral Loss of Heterozygosity and KMT2A Partial Tandem Duplication Identified By Chromosomal Genomic Array Testing (CGAT) Correlated with Decreased Overall Survival in Acute Myeloid Leukemia (AML)
- Journal / Conference
- ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), oral
- Year
- 2024
- Research Committee(s)
- Lymphoma
Lack of benefit of autologous hematopoietic cell transplantation (auto-HCT) in mantle cell lymphoma (MCL) patients (pts) in minimal residual disease (MRD)-negative first complete remission (CR): Initial report from ECOG-ACRIN EA4151
- Journal / Conference
- ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), poster
- Year
- 2024
- Research Committee(s)
- Lymphoma
- Study Number(s)
- CTSU/A052101
Trial in Progress – Alliance A052101: A randomized phase 3 trial of continuous vs. intermittent maintenance therapy with zanubrutinib as upfront treatment in older patients with mantle cell lymphoma
- Journal / Conference
- ABRCMS 2024 Graduate Symposium (Nov. 13-16 in Pittsburgh, PA), poster
- Year
- 2024
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- Study Number(s)
- S1609
Outcome and Treatment Toxicity at Community versus Academic Sites for Patients with Rare Cancers on Immune Checkpoint Inhibitors (NCI/SWOG S1609)
- Journal / Conference
- Journal of Clinical Oncology Dec 13:JCO2401383. doi: 10.1200/JCO-24-01383. Online ahead of print
- Year
- 2024
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID39671534
- Study Number(s)
- S1815
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers (SWOG S1815; NCT#03768414)
- Journal / Conference
- JAMA Oncology Dec 5:djae314. doi: 10.1093/jnci/djae314. Online ahead of print
- Year
- 2024
- Research Committee(s)
- Breast
- Study Number(s)
- S1007
Race and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Positive BC in the Phase III RxPONDER Trial (SWOG S1007)
- Journal / Conference
- Journal of Thoracic Oncology Nov 4:S1556-0864(24)02431-6
- Year
- 2024
- Research Committee(s)
- Lung
- PMID
- PMID39505259
- Study Number(s)
- S1929
Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer. S1929
- Journal / Conference
- Journal of Clinical Oncology Sep;25(9):1147-1162
- Year
- 2024
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- S1613
Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patient with RAS/BRAF wild-type, HER2-positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase 2 Trial
- Journal / Conference
- JNCI Monographs
- Year
- 2024
- Research Committee(s)
- Cancer Care Delivery
- Study Number(s)
- S1415CD
Intracluster Correlation Coefficients from Cluster Randomized Trials Conducted within the NCI Community Oncology Research Program (NCORP)
- Journal / Conference
- Haematologica Jan 1;108(1):42-47
- Year
- 2023
- Research Committee(s)
- Leukemia
- PMID
- PMID35833298
- PMC
- PMC9827148
- Study Number(s)
- S0106, S1203, SWOG-8600, SWOG-9031